Taiwan FDA registration cf78eefd7ef5939a8fe540a11298e748
Boyi's first generation blood glucose measurement system
TW: 博依第一代血糖量測系統
Taiwan·Risk Class 2·EPS BIO TECHNOLOGY CORP.·Registered May 20, 2013 – Sep 23, 2021CancelledRegistration details
- Analysis ID
- cf78eefd7ef5939a8fe540a11298e748
Company information
- Manufacturer
- EPS BIO TECHNOLOGY CORP.
- Manufacturer Country
- Taiwan, Province of China
- Authorized Representative
- EPS BIO TECHNOLOGY CORP.
Product details
- Intended Use
- It is used for in vitro measurement of blood glucose content in fresh microvascular whole blood samples and is not suitable for neonatal testing.
- Product Type (Level 1)
- A Clinical chemistry and clinical toxicology
- Product Type (Level 2)
- A.1345 Glucose Test System
- Import Information
- Domestic
Dates and status
- Registration Date
- May 20, 2013
- Expiry Date
- Sep 23, 2021
- Cancellation Date
- Sep 08, 2023
Cancellation information
- Status
- Logged out
- Reason
- 未展延而逾期者
About this record
Access comprehensive regulatory information for Boyi's first generation blood glucose measurement system in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number cf78eefd7ef5939a8fe540a11298e748 and manufactured by EPS BIO TECHNOLOGY CORP.. The authorized representative in Taiwan is EPS BIO TECHNOLOGY CORP..
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Free DatabasePowered by Pure Global AI89,000+ Devices